Competition, capital growth and risk-taking in emerging markets: Policy implications for banking sector stability during COVID-19 pandemicResearch Article Published on 2021-06-242022-10-28 Journal: PLoS ONE [Category] Coronavirus, MERS, SARS, [키워드] cause Characteristics competition Concentration country COVID-19 pandemic Evidence growth higher risk implication MENA Middle East North Policy positive Regulatory regulatory authority risk stability Topic [DOI] 10.1371/journal.pone.0253803 PMC 바로가기 [Article Type] Research Article
JAK-STAT Pathway Inhibition and their Implications in COVID-19 TherapyJAK-STAT 경로 억제 및 COVID-19 치료에 미치는 영향Review Published on 2021-06-012022-09-11 Journal: Postgraduate medicine [Category] 유전자 메커니즘, 치료법, [키워드] 3CL pro activated Activation adverse effects B cell Baricitinib clinical trial contrary COVID-19 COVID-19 patients COVID-19 therapy cytokine cytokine receptor cytokine signaling Cytokine storm dendritic cell dendritic cells determine Disease progression disease severity Efficacy effort endothelial cells envelope protein envelope proteins excessive inflammation Host hosts immune response immune responses implicated incidence of COVID-19 increase Inflammation Inflammatory marker inflammatory markers Inflammatory mediators inhibition inhibitor inhibitors Jak Jak-STAT JAK/STAT JAK/STAT pathway JAK/STAT signaling janus Janus kinase Lymphocytes macrophages mechanism membrane molecular Monocytes natural killer cell Natural killer cells nucleocapsid nucleus Phosphorylation Pneumocytes progression promote protease Proteases Protein recruitment reduce Regulatory Authorities regulatory authority required ruxolitinib SARS-CoV-2 SARS-COV-2 infection severity signaling cascade signaling cascades STAT STATs structural protein structural proteins supported suppressor suppressors survival T cell the disease Therapeutic strategies therapeutic strategy Tofacitinib translate Trigger tyrosine [DOI] 10.1080/00325481.2020.1855921 PMC 바로가기 [Article Type] Review
IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?IABS/CEPI 플랫폼 기술 웨비나: 백신 개발 시간 단축이 가능한가?Article Published on 2021-06-012022-08-31 Journal: Biologicals : journal of the International Associa [Category] MERS, SARS, 변종, 신약개발, [키워드] Alliance backbone Biological Biological Standardization Coalition component COVID-19 COVID-19 vaccine development disease Diseases Emerging infectious diseases faster Genetic Infectious diseases Innovation input joint meeting organized pandemic pathogen Pathogens platform Platform technology protein sequences rapid response reduce Regulatory Regulatory Authorities regulatory authority SARS-CoV-2 the vaccine Vaccine development variants of SARS-CoV-2 [DOI] 10.1016/j.biologicals.2021.04.005 PMC 바로가기 [Article Type] Article
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)Commentary Published on 2021-05-312022-10-29 Journal: Journal of Pharmaceutical Policy and Practice [Category] COVID-19, [키워드] administration adverse event Analysis aspiration pneumonia association benefit BNT162b2 cardiovascular disease causal link cause coronavirus vaccine death died event FIVE hemorrhage Hemorrhagic ICH incidence incompatible Japan Japanese men men and women mortality data Pfizer-BioNTech raised regulatory authority report reported reveal Statistics stroke the vaccine thrombosis venous women [DOI] 10.1186/s40545-021-00326-7 PMC 바로가기 [Article Type] Commentary
Politics overwhelms science in the Covid-19 pandemic: Evidence from the whole coverage of the Italian quality newspapersResearch Article Published on 2021-05-202022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, [키워드] ad-hoc addressed Analysis analyzed article Classifier Coverage dataset eight Health health emergency Italian knowledge linear Logistic regression media Metrics National outbreak pandemic Quantitative analysis Regulation regulatory authority SARS-CoV-2 SARS-CoV-2 pandemic the SARS-CoV-2 Topic treat [DOI] 10.1371/journal.pone.0252034 PMC 바로가기 [Article Type] Research Article
Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potencyCOVID-19 회복기 혈장 효능에 대한 병원체 감소 기술의 영향Editorial Published on 2021-05-012022-09-12 Journal: Transfusion clinique et biologique : journal de la [Category] 진단, [키워드] Concentration convalescent convalescent plasma COVID-19 COVID-19 convalescent plasma COVID19 detrimental Efficacy Evidence IgG IgG subclasses Impact Infection lack NAb Neutralizing antibodies neutralizing antibody Pathogen inactivation Pathogen reduction technologies. reduction regulatory authority residual risk while [DOI] 10.1016/j.tracli.2021.02.005 PMC 바로가기 [Article Type] Editorial
Measuring Progress of Regulatory Convergence and Cooperation Among Asia–Pacific Economic Cooperation (APEC) Member Economies in the Context of the COVID-19 PandemicOriginal Research Published on 2021-04-112022-10-29 Journal: Therapeutic innovation & regulatory science [Category] COVID-19, MERS, SARS, [키워드] accelerate addition APEC approval Certificate collected concerning Context convergence cooperation COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines diagnostics Economy effort example Forum GMP good manufacturing practice harmonization highlight increase in Innovation Key performance indicators life maintain member multisite New patients Progress Regulatory regulatory authority Regulatory convergence Regulatory cooperation Result Safe Science steering committee Treatment [DOI] 10.1007/s43441-021-00285-w PMC 바로가기 [Article Type] Original Research
The time is now: role of pragmatic clinical trials in guiding response to global pandemics지금이 바로 지금입니다: 세계적인 유행병에 대한 대응을 안내하는 실용적인 임상 시험의 역할Review Published on 2021-03-242022-09-10 Journal: Trials [Category] 신약개발, 임상, [키워드] Adaptive trials design alternative blunt clinical evidence clinical trial coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic Efficacy Electronic health records-embedded research Epidemic Evidence evidence of facilitate generate highlight implementation inefficient morbidity morbidity and mortality pandemic Pandemics platform Pragmatic Pragmatic clinical trials randomized clinical trial Regulatory Authorities regulatory authority Research several limitation several limitations subsequent Treatment widespread [DOI] 10.1186/s13063-021-05165-0 PMC 바로가기 [Article Type] Review
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials단회 투여 및 ChAdOx1 nCoV-19(AZD1222) 백신의 면역원성 및 효능에 대한 추가 투여 시간의 영향: 4건의 무작위 시험에 대한 통합 분석Meta-Analysis Published on 2021-03-062022-09-10 Journal: Lancet (London, England) [Category] MERS, SARS, 임상, [키워드] 1:1 95% CI addition administration Ageusia All participants Analysis Anosmia antibody antibody levels Antibody Response Antibody responses approved assigned AstraZeneca AZD1222 baseline binding antibody booster dose booster doses Brazil category ChAdOx1 ChAdOx1 nCoV-19 Clinical research Coalition control group control vaccine cough COV005 COVID-19 COVID-19 disease COVID-19-related death Cutoff death defined described dose doses double-blind Efficacy Emergency use Endpoint Evidence evidence of exclusion exploratory Exploratory analyses Exploratory analysis Fever finding first dose FIVE Follow-up for inclusion foundation funding geometric mean geometric mean ratio GMR had no Hospital admission immunoassay immunogenicity immunogenicity data independent indicated individual Infection initial Innovation interim analysis ISRCTN89951424 less lower dose Medicine Medicines Medicines and Healthcare products Regulatory Agency Melinda Gate Melinda Gates N protein NAAT NAAT-positive swab network neutralisation NIHR no evidence of nucleic acid nucleic acid amplification nucleic acid amplification test observation offered Older outcomes Oxford pandemic participant phase 2/3 phase 3 study positive swab primary analysis primary endpoint Primary outcome prime-boost interval priming PROTECT pseudovirus randomised controlled Randomised trial Randomly receive receiving recruited regimen Registered regulatory authority response Safety saline placebo SARS-COV-2 infection SARS-CoV-2 N protein second dose secondary Serious Adverse Events seronegative Seven Shortness of breath single-blind Single-dose South South Africa Standard dose subset supported Swab swabs Symptom symptomatic COVID-19 disease symptomatic infection Telle the primary endpoint the timing the vaccine Trial vaccination Vaccine vaccine efficacy Valley Viral Viral particles [DOI] 10.1016/S0140-6736(21)00432-3 PMC 바로가기 [Article Type] Meta-Analysis
Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implicationsWHO 데이터베이스에서 렘데시비르로 인한 의심되는 약물 부작용에 대한 신속한 검토 발견 및 시사점Article Published on 2021-01-012022-09-11 Journal: Expert review of clinical pharmacology [Category] SARS, 치료제, [키워드] ADE ADEs adverse drug events age America Americas Case report COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients creatinine Deterioration duplicate duplicates Effectiveness enzyme event Factor hepatic enzyme hepatic enzyme changes hepatic enzymes implication increase in Injury Kidney function liver liver and kidney function main outcome measure majority male management objective organ Patient patients with COVID-19 promise Rapid reduced regulatory authority Remdesivir renal renal injury reported Respiratory failure Result seriousness shown the WHO Vigibase® were excluded WHO [DOI] 10.1080/17512433.2021.1856655 PMC 바로가기 [Article Type] Article